{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:29:12Z","timestamp":1786343352106,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:00:00Z","timestamp":1786233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate\u2010577 trial, Grade 3\u20135 nivolumab\u2010related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real\u2010world data on immunotherapy\u2010related adverse events (irAEs) are limited. This study assessed the cumulative incidence of irAEs in a real\u2010world setting. In this retrospective cohort study, all patients receiving \u2265\u20091\u2009cycle of adjuvant nivolumab at three Dutch gastroesophageal cancer centers were included. Clinical data were extracted from electronic records. The primary outcome was the cumulative incidence of Grade 3\u20135 irAEs. Secondary outcomes included predictors, timing, and clinical outcomes of Grade 3\u20135 irAEs, and cumulative incidence of Grade 2 irAEs. Among 142 patients with median follow\u2010up 27.9\u2009months, Grade 3\u20135 irAEs occurred in 15%. Hepatitis (3%), pneumonitis (2%), and myocarditis (2%) were most common. Two fatal irAEs occurred (1%). Median time to first Grade 3\u20135 irAE was 2.0\u2009months (IQR 0.7\u20136.4). Grade 3\u20135 irAEs led to hospitalization in 9%, required systemic corticosteroids in 11%, and resulted in clinical sequelae in 8%. No predictors for Grade 3\u20135 irAEs were identified. Early discontinuation due to any irAE occurred in 24%. In conclusion, severe irAEs (Grade 3\u20135) occurred more frequently than in CheckMate\u2010577 and often required hospitalization and immunosuppression, with sequelae in a significant proportion. Discontinuation due to irAEs was higher than in CheckMate\u2010577 (24% vs. 9%). Careful risk\u2013benefit assessment and active monitoring during adjuvant nivolumab therapy are warranted.<\/jats:p>","DOI":"10.1002\/ijc.70686","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:51:05Z","timestamp":1786341065000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real\u2010World Study"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6392-2858","authenticated-orcid":false,"given":"Michelle","family":"Koops van \u2019t Jagt","sequence":"first","affiliation":[{"name":"Department of Medical Oncology University Medical Center Groningen (UMCG)  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniek","family":"Strijdhorst","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Amsterdam University Medical Center, Location University of Amsterdam  Amsterdam the Netherlands"},{"name":"Cancer Center Amsterdam, Cancer Treatment and Quality of Life  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6141-9796","authenticated-orcid":false,"given":"Tamara Jessica","family":"Huizer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Erasmus Medical Center (EMC)  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Albertien","family":"Kleibeuker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Medical Center Groningen (UMCG)  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[{"name":"Cancer Center Amsterdam, Cancer Treatment and Quality of Life  Amsterdam the Netherlands"},{"name":"Department of Medical Oncology Amsterdam UMC, Location Free University  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Mostert","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Erasmus Medical Center (EMC)  Rotterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"van Laarhoven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Amsterdam University Medical Center, Location University of Amsterdam  Amsterdam the Netherlands"},{"name":"Cancer Center Amsterdam, Cancer Treatment and Quality of Life  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacco Juri","family":"de Haan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology University Medical Center Groningen (UMCG)  Groningen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,9]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"E209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung H.","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"E1564","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global Burden of Oesophageal and Gastric Cancer by Histology and Subsite in 2018","volume":"69","author":"Arnold M.","year":"2020","journal-title":"Gut"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"E2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer","volume":"366","author":"Van Hagen P.","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"E323","DOI":"10.1056\/NEJMoa2409408","article-title":"Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer","volume":"392","author":"Hoeppner J.","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103067","article-title":"Real\u2010World Outcomes of the CROSS Regimen in Patients With Resectable Esophageal or Gastro\u2010Esophageal Junction Adenocarcinoma: A Nationwide Cohort Study in The Netherlands","volume":"80","author":"Laarhoven H.","year":"2025","journal-title":"EClinicalMedicine"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"E1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune Checkpoint Therapy\u2014Current Perspectives and Future Directions","volume":"186","author":"Sharma P.","year":"2023","journal-title":"Cell"},{"key":"e_1_2_12_8_1","volume-title":"StatPearls [Internet]","author":"Rendon A.","year":"2025"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"E1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant Nivolumab Versus Ipilimumab in Resected Stage IIIB\u2010C and Stage IV Melanoma (CheckMate 238): 4\u2010Year Results From a Multicentre, Double\u2010Blind, Randomised, Controlled, Phase 3 Trial","volume":"21","author":"Ascierto P. A.","year":"2020","journal-title":"Lancet Oncology"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"E683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab After Nephrectomy in Renal\u2010Cell Carcinoma","volume":"385","author":"Choueiri T. K.","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"E2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab Versus Placebo in Muscle\u2010Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin D. F.","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune\u2010Related Adverse Events of Immune Checkpoint Inhibitors: A Review","volume":"14","author":"Yin Q.","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association Between Immune\u2010Related Side Effects and Efficacy and Benefit of Immune Checkpoint Inhibitors\u2014A Systematic Review and Meta\u2010Analysis","volume":"92","author":"Hussaini S.","year":"2021","journal-title":"Cancer Treatment Reviews"},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"E1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly R. J.","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","unstructured":"R. J.Kelly J. A.Ajani J.Kuzdzal et\u00a0al. \u201cAdjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (EC\/GEJC) Following Neoadjuvant Chemoradiotherapy (CRT): First Results of Overall Survival (OS) From CheckMate 577 \u201d(2025) Presented at 2025 ASCO Annual Meeting Chicago IL.","DOI":"10.1200\/JCO.2025.43.16_suppl.4000"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"E7953","DOI":"10.3390\/curroncol29100629","article-title":"Long\u2010Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients","volume":"29","author":"Tong J.","year":"2022","journal-title":"Current Oncology"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15225317","article-title":"Adjuvant Immunotherapy in Curative Intent Esophageal Cancer Resection Patients: Real\u2010World Experience Within an Integrated Health System","volume":"15","author":"Kwak H. V.","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"E632","DOI":"10.1016\/j.xjon.2025.10.003","article-title":"Real\u2010World Utilization of Adjuvant Nivolumab Among Esophageal and Gastroesophageal Junction Cancer Patients at a Large Integrated Health System","volume":"28","author":"Gochi A. M.","year":"2025","journal-title":"JTCVS Open"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"E1500","DOI":"10.1016\/j.ijsu.2014.07.014","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration","volume":"12","author":"Vandenbroucke J. P.","year":"2014","journal-title":"International Journal of Surgery"},{"key":"e_1_2_12_20_1","unstructured":"National Cancer Institute \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 \u201daccessed January 20 2025 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"E1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of Toxicities From Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow\u2010Up","volume":"33","author":"Haanen J.","year":"2022","journal-title":"Annals of Oncology"},{"key":"e_1_2_12_22_1","unstructured":"IBM Corp \u201cIBM SPSS Statistics for Windows [Software]. Version 28.0 \u201d(2021) Armonk NY: IBM Corp."},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","article-title":"Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer","volume":"12","author":"Rice T. W.","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41525-022-00345-6","article-title":"Germline Genetic Variation and Predicting Immune Checkpoint Inhibitor Induced Toxicity","volume":"7","author":"Chin I. S.","year":"2022","journal-title":"NPJ Genomic Medicine"},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115053","article-title":"Immune\u2010Related Adverse Events in a Nationwide Cohort of Real\u2010World Melanoma Patients Treated With Adjuvant Anti\u2010PD1 \u2010 Seasonal Variation and Association With Outcome","volume":"212","author":"Jurlander R. S.","year":"2024","journal-title":"European Journal of Cancer"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194823","article-title":"Real\u2010World Effectiveness, Safety, and Health\u2010Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL","volume":"15","author":"Rogiers A.","year":"2023","journal-title":"Cancers"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","article-title":"Combining Surgery and Immunotherapy: Turning an Immunosuppressive Effect Into a Therapeutic Opportunity","volume":"6","author":"Bakos O.","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150754","article-title":"PD\u20101 Blockade Attenuates Surgery\u2010Mediated Immunosuppression and Boosts Th1 Immunity Perioperatively in Oesophagogastric Junctional Adenocarcinoma","volume":"14","author":"Davern M.","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"E1132","DOI":"10.1001\/archsurg.141.11.1132","article-title":"Cell Response to Surgery","volume":"141","author":"Choileain N. N.","year":"2006","journal-title":"Archives of Surgery"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"E760","DOI":"10.1016\/S1470-2045(03)01282-8","article-title":"Excisional Surgery for Cancer Cure: Therapy at a Cost","volume":"4","author":"Coffey J. C.","year":"2003","journal-title":"Lancet Oncology"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"E1345","DOI":"10.1007\/s12029-024-01092-w","article-title":"Efficacy and Safety of Salvage\u2010Line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses","volume":"55","author":"Murashima Y.","year":"2024","journal-title":"Journal of Gastrointestinal Cancer"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"E1016","DOI":"10.1177\/10781552231199048","article-title":"Utilization and Toxicity Patterns of 2\u2010Weekly (Q2W) Versus 4\u2010Weekly (Q4W) Nivolumab for Treatment of Adjuvant and Metastatic Melanoma at BC Cancer","volume":"30","author":"Truong J.","year":"2024","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071054","article-title":"Sex\u2010Related Differences in Immunotherapy Toxicities: Insights Into Dimorphic Responses","volume":"17","author":"Canzian J.","year":"2025","journal-title":"Cancers"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"E89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body Mass Index and Immune\u2010Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapies: A Systematic Review and Meta\u2010Analysis","volume":"70","author":"Guzman\u2010Prado Y.","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"E1474","DOI":"10.1200\/JCO.21.02377","article-title":"Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials","volume":"40","author":"Unger J. M.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_12_36_1","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1038\/s41467-023-44512-4","article-title":"Polygenic Risk Score for Ulcerative Colitis Predicts Immune Checkpoint Inhibitor\u2010Mediated Colitis","volume":"15","author":"Middha P.","year":"2024","journal-title":"Nature Communications"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"E545","DOI":"10.1038\/s41591-022-01698-2","article-title":"Intestinal Microbiota Signatures of Clinical Response and Immune\u2010Related Adverse Events in Melanoma Patients Treated With Anti\u2010PD\u20101","volume":"28","author":"McCulloch J. A.","year":"2022","journal-title":"Nature Medicine"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and Interleukin\u20106 Are Prognostic Factors for Autoimmune Toxicity Following Treatment With Anti\u2010CTLA4 Blockade","volume":"16","author":"Valpione S.","year":"2018","journal-title":"Journal of Translational Medicine"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline Circulating IL\u201017 Predicts Toxicity While TGF\u2010\u03b21 and IL\u201010 Are Prognostic of Relapse in Ipilimumab Neoadjuvant Therapy of Melanoma","volume":"3","author":"Tarhini A. A.","year":"2015","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"E1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating Cytokines Predict Immune\u2010Related Toxicity in Melanoma Patients Receiving Anti\u2010PD\u20101\u2013Based Immunotherapy","volume":"25","author":"Lim S. Y.","year":"2019","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"E917","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre\u2010Existing Autoimmune Disease and the Risk of Immune\u2010Related Adverse Events Among Patients Receiving Checkpoint Inhibitors for Cancer","volume":"68","author":"Kehl K. L.","year":"2019","journal-title":"Cancer Immunology, Immunotherapy"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70686","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70686","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:51:11Z","timestamp":1786341071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":40,"alternative-id":["10.1002\/ijc.70686"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70686","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,9]]},"assertion":[{"value":"2026-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijc.70686"}}